Rocket Lab’s Sharp Decline Creates a Divergent Narrative
Rocket Lab USA (NASDAQ: RKLB) has become a tale of two tapes. The small-launch leader’s shares have tumbled 57% from their all-time high of $151 reached in June 2026, yet the Street’s consensus price target sits at $111.31 — implying a 49% upside from current levels. This stark disconnect raises a critical question for growth-oriented investors: is the market overlooking fundamental momentum, or are analysts too optimistic about a capital-intensive space venture?
Fundamental Momentum Is Building
Beneath the price carnage, Rocket Lab’s operational engine is accelerating. In the first quarter of 2026, the company secured a record 31 launch contracts — more than it signed in all of 2025. Revenue surged 64% year-over-year to $200 million, driven by both its Electron launch vehicle and its growing Space Systems division, which manufactures satellite components and subsystems.
Perhaps the most telling metric is the backlog. Contracted future revenue now stands at $2.2 billion, up 108% from the year-ago quarter. This visibility is rare in the launch industry, where manifest uncertainty often clouds forecasts. Additionally, adjusted EBITDA loss narrowed to $11.8 million, significantly better than the $26 million loss analysts had modeled, suggesting operating leverage is beginning to materialize.
Government Contracts Provide a Floor
Two major U.S. Space Force awards underscore Rocket Lab’s strategic importance. A $397 million contract tasks the company with developing, launching, and operating advanced flat satellites using its forthcoming Neutron medium-lift rocket. A separate $266 million deal covers 12 suborbital launches plus options for six more, with the first flight slated before year-end. These contracts not only fund Neutron’s development but also anchor a long-term revenue stream from the defense sector — a key differentiator versus purely commercial launch peers.
Risks Remain Elevated
Despite the contract wins, Rocket Lab is not yet profitable. The company posted a $45 million net loss in Q1 2026, and its price-to-sales (P/S) ratio of 53x dwarfs the technology sector average of roughly 7x. Such a premium valuation demands flawless execution. Moreover, the stock often trades in sympathy with SpaceX — a private company whose valuation swings via secondary markets can spill over into public space names. Investors should also monitor Neutron’s development timeline; delays could compress the upside analysts are modeling.
Verdict: A High-Conviction Speculative Bet
For investors with a high risk tolerance and a multi-year horizon, Rocket Lab offers a rare combination: a proven launch cadence, a maturing satellite-manufacturing business, and government-backed development funding for a next-generation rocket. The 49% analyst upside is plausible if Neutron enters service on schedule and margins expand. However, given the lofty P/S ratio and ongoing losses, a starter position — rather than a full allocation — is prudent until profitability inflects.
Frequently Asked Questions
- Why has Rocket Lab stock fallen 57% from its high? The decline reflects broader risk-off sentiment toward high-multiple growth stocks, concerns about the capital intensity of Neutron development, and profit-taking after a strong 2025 run. The selloff appears more macro-driven than company-specific.
- What contracts are driving analyst optimism? The $2.2 billion backlog, a $397 million Space Force satellite contract, and a $266 million suborbital launch deal provide multi-year revenue visibility. At least seven analysts raised targets after Q1 results highlighted accelerating sales and better-than-expected EBITDA.
- Is Rocket Lab profitable? Not yet. The company recorded a $45 million net loss in Q1 2026. However, adjusted EBITDA losses are narrowing, and management has guided toward breakeven as Neutron ramps and Space Systems margins improve.
